Friday, 20 Apr 2018

You are here

RheumNow Week in Review – 26 August 2016

Dr. Jack Cush reviews news and journal reports from the past week on RheumNow.com.

  1. Japanese study 345 RA pts shows sustained high CRP levels associated with increased risk of CKD (~20%) https://t.co/VWOxuHOCDl
  2. Gout patients have a 17% increased risk of fracture (limbs & spine). Interestingly allopurinol use lowers risk http://buff.ly/2c1V2kI
  3. SPIRIT-P1 Study published in Lancet; Ixekizumab (Taltz), IL-17 inhibitor, better than Placebo, but same as Humira at 24wks in psoriatic arthritis outcomes; but Taltz superior to Humira at Psoriasis outcomes. https://t.co/mVZ0sMSHdX
  4. Hypotony (low intraocular pressure) is a sign of active, severe & usually symptomatic uveitis in Juvenile Arthritis https://t.co/qJOAWPcPpW
  5. RCT of osteoporotic vertebral fractures (< 6 wks) showed vertebroplasty twice better than placebo in reducing pain https://t.co/aIeKdXTU1C
  6. Risk factors for marginal ulcers in obesity gastric bypass surgery:Diabetes, Hx PUD, PPI & ASA use. But limited doses of. NSAIDs was not signif!cantly associated. PPI may be due to confounding by indication. https://t.co/9Ct4Xvmp2J
  7. DESIR early SpA Cohort - Structural progression is low (~5%) in early SpA; Sacroiliitis risk factors were B27, smoking & MRI SI inflammation https://t.co/MWsxlbb6lt
  8. Idiopathic Recurrent Pericarditis follows ~20% acute pericarditis; responds VERY well to IL-1 inhibition (anakinra) https://t.co/T28ggiTGyA
  9. Since FDA approval 2011, Benlystas uptake has been slow, but had $265 million in worldwide sales in 2014. https://t.co/hqViTE0PEs
  10. PsA have the same cancer & serious infx rates as non-PsA; but have more hematologic cancers & opportunistic infxns https://t.co/Mm9Ehpd19F
  11. Prior Cancer Patients May Safely Receive TNF Inhibitors or Rituximab
  12. Adalimumab Controls Non-Infectious Uveitis in VISUAL II Study
  13. Risk of Sepsis or Death Lower with Biologics in Rheumatoid Arthritis.
  14. EULAR 2016: Name that Country
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review – Vitamin D Snark Report (4.20.18)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.  A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.

RheumNow Week in Review - Do you Dig Shingrix? (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlights includes manpower shortfalls, comorbidities in AA Lupus, certolizumab pregnancy safety, which Shingles vaccine is best and the power of combination biologics in severe refractory  SLE.

"Breakthrough" Drug Designation by the FDA

The current issue of the NEJM reviews the Food and Drug Administration (FDA) “breakthrough therapy” designation that was introduced in 2012 to expedite testing and approval of medications that were intended to treat serious or life-threatening conditions.  This status is granted when preliminary evidence with a new drug suggests substantial benefits over existing therapies for these unfortunate conditions.

ACR Projects Significant Manpower Shortages for 2030

Arthritis & Rheumatology has published the results of the 2015 Workforce Study of Rheumatology Specialists, and estimates a current shortage (demand > supply) of 700 (12.9%) full-time rheumatologists and that this deficit will worsen (102%) to 4133 FTE by 2030.

RheumNow Week in Review -The Temporal Artery Biopsy Letdown (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on the cost of RA care, infections on planes, CV events and Sacroiliitis in IBD, NXP-2 antibodies and calcinosis and rituximab in myositis ILD patients.